Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Shulman

Showing results (401-410 of 422) with videos related to

Pageof 43
Sort By:
Blood|April 17, 2013
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trialPeter W Hunt, Nancy S Shulman, Timothy L Hayes, et al.
Pediatric Blood & Cancer|July 21, 2020
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumorKevin X Liu, Natalie B Collins, Katie A Greenzang, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Translational Oncology|June 18, 2026
Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcomaHelen F Gloege, Maria Ana Isabel C De Los Santos, Advaita Chakraborty, et al.
Cancer|July 2, 2026
Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor StudyDuncan C Ramsey, David S Shulman, Grace C Zhou, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology GroupRiaz Gillani, David S Shulman, Natalie J DelRocco, et al.
Open Forum Infectious Diseases|September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2025
Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology GroupRiaz Gillani, David S Shulman, Natalie J DelRocco, et al.
Pageof 43

Showing results (401-410 of 422) with videos related to

Sort By:
Pageof 43
Blood|April 17, 2013
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trialPeter W Hunt, Nancy S Shulman, Timothy L Hayes, et al.
Pediatric Blood & Cancer|July 21, 2020
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumorKevin X Liu, Natalie B Collins, Katie A Greenzang, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Translational Oncology|June 18, 2026
Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcomaHelen F Gloege, Maria Ana Isabel C De Los Santos, Advaita Chakraborty, et al.
Cancer|July 2, 2026
Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor StudyDuncan C Ramsey, David S Shulman, Grace C Zhou, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology GroupRiaz Gillani, David S Shulman, Natalie J DelRocco, et al.
Open Forum Infectious Diseases|September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2025
Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology GroupRiaz Gillani, David S Shulman, Natalie J DelRocco, et al.
Pageof 43